Vyera Pharmaceuticals
Pharmaceutical company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Vyera Pharmaceuticals?
Summarize this article for a 10 year old
Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.[2][3]
Company type | Private |
---|---|
Industry | Pharmaceuticals |
Founded | February 2015; 9 years ago (2015-02) |
Founder | |
Headquarters | New York City and Zug, Switzerland |
Key people | Justin Garrett[1] Chief Executive Officer |
Products | Vecamyl, Daraprim |
Website | www |
The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension. The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. The company's stock price dropped around 10% after the price increase of the drug.[4] CEO Martin Shkreli faced immense criticism for his actions.[5] The company was named after Alan Turing, the computer scientist.
On May 10, 2023, Vyera filed for Chapter 11 bankruptcy.[6]